Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27526789 | 0.79 | KIF11 (0.52) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL820736 | 0.77 | KIF11 (0.71) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL6428302 | 0.77 | KIF11 (0.50) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL65312 | 0.77 | KIF11 (0.71) | KIF11LMNAMAPTCYP19A1USP2 | |
| Water SCHEMBL9183302 | 0.76 | TSHR (0.38) | KIF11LMNAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL15140525 | 0.74 | KIF11 (0.68) | KIF11LMNAMAPTCYP19A1USP2 | |
| Lithium SCHEMBL29576172 | 0.74 | KIF11 (0.68) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL28443995 | 0.74 | KIF11 (0.68) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL20137330 | 0.74 | KIF11 (0.68) | KIF11LMNAMAPTCYP19A1USP2 | |
| SCHEMBL29245411 | 0.74 | KIF11 (0.68) | KIF11LMNAMAPTCYP19A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10179792-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | KIF11 3180/4885LMNA 1800/4885MAPT 2309/4885 |
| US-10179792-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885LMNA 453/4885MAPT 4660/4885 |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885LMNA 453/4885MAPT 4660/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | KIF11 3180/4885LMNA 1800/4885MAPT 2309/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | KIF11 3180/4885LMNA 1800/4885MAPT 2309/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885LMNA 453/4885MAPT 4660/4885 |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | KIF11 3328/4885LMNA 3508/4885MAPT 2892/4885 |
| US-20210283077-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885LMNA 453/4885MAPT 4660/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | KIF11 3180/4885LMNA 1800/4885MAPT 2309/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | KIF11 4315/4885LMNA 453/4885MAPT 4660/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | KIF11 3180/4885LMNA 1800/4885MAPT 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.